LB1410 + lenvatinib

LB1410 + lenvatinib is a combination therapy developed by L & L Biopharma for the treatment of advanced malignancies, including anti-PD-1 resistant cervical cancer and renal cell carcinoma. LB1410 is a recombinant humanized bispecific antibody that simultaneously targets the immune checkpoints Programmed Cell Death Protein 1 (PD-1) and T-cell Immunoglobulin and Mucin-domain containing-3 (TIM-3). By blocking these pathways, LB1410 aims to reverse T-cell exhaustion and restore anti-tumor immune responses in patients who have become refractory to standard PD-1/PD-L1 inhibitors. Lenvatinib is a small molecule tyrosine kinase inhibitor (TKI) with potent anti-angiogenic properties, targeting Vascular Endothelial Growth Factor Receptors (VEGFR1-3), Fibroblast Growth Factor Receptors (FGFR1-4), Platelet-Derived Growth Factor Receptor alpha (PDGFRα), KIT, and RET. The combination approach is designed to synergistically enhance therapeutic efficacy by simultaneously modulating the immunosuppressive tumor microenvironment and inhibiting tumor angiogenesis.

Other names

LB1410 + tyrosine kinase inhibitorLB1410 + TKILB1410 plus lenvatinibLB-1410 plus lenvatinibLB 1410 plus lenvatinib